Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
about
Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsRoutes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in miceEffect of vaccine administration modality on immunogenicity and efficacy.Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacyCytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemiaEnhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsCpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathwayTrial Watch: Experimental Toll-like receptor agonists for cancer therapyReevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin.CpG Oligodeoxynucleotide Inhibits Cockroach-Induced Asthma via Induction of IFN-γ⁺ Th1 Cells or Foxp3⁺ Regulatory T Cells in the Lung.Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinomaFully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivoCpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Combination strategies to enhance antitumor ADCC.Toll-like Receptors in Chronic Lymphocytic Leukemia.Anti-tumour strategies aiming to target tumour-associated macrophages.Toll-like receptor agonists: a patent review (2011 - 2013).A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.Injection site reactions after subcutaneous oligonucleotide therapyBiological Response Modifier in Cancer Immunotherapy.A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.Microenvironmental Effects of Cell Death in Malignant Disease.A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide deliveryAcademic Cancer Center Phase I Program Development.Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.The revival of CpG oligonucleotide-based cancer immunotherapies.
P2860
Q27025290-962AFDE4-58FD-450D-90A0-F20755758F24Q27335400-C04208E7-91FB-41FB-8352-9AC6EB451B17Q27692376-2F016270-D82B-4D3D-8252-1DD4D30C65F4Q28354371-7DC7BEA1-C71D-4AEF-99DF-0CA918117AE4Q33910990-55A915F8-D72B-42ED-B70F-80866F98F967Q34047191-6394302E-8D1B-4C1F-8355-B89BE877D963Q34048170-C2541459-E6DA-4177-8192-ABB6E14483A5Q36030989-225AE66E-06BA-4456-9BC3-56DFD56ED9ADQ36140670-49ED1C2C-DA44-411E-9A5F-BF46D6D0EF7EQ36194849-6683D061-89E9-4FC7-8440-7A94F51301C4Q36413659-5F49F3FC-4BE2-4136-AB64-0FA504C92077Q36636607-5EDF388E-A882-4CB2-8AE9-EC6583A8E2C9Q36884862-B1E0FFCF-D739-4AAC-AD9C-20B6B319D3E2Q37044950-05F1D434-FA6F-40D4-8A40-ECC9F1C5B9E5Q37521856-96F55F43-7705-4544-A989-443126F9786AQ37671216-DF105989-3B8B-4326-9B79-276BB2E7A800Q38014085-DBF92444-68DF-41A4-85F0-B6FB97D8AAFAQ38042942-B6AAA393-4AFA-4223-8BF3-1F75D0AB8577Q38056746-91F10DC7-96B2-4AC2-A565-9226D290765CQ38181176-16907996-612B-4319-A78D-752FE00DEEFBQ38259725-F8021F90-B96D-4CB4-B8D5-418D3DBD296BQ38298483-BC01EED3-08B6-43DF-9C45-4A6C53F1A4A1Q38803235-13C4D005-F425-436A-9DAE-2B0747ADE0BCQ38848213-33315F50-A2C2-4B38-8E3B-ACA8D8B02A5AQ38926456-D2F692E3-D3E0-4D6E-A3D3-BE053D77366EQ38936695-1F379CB5-0018-47AA-B3BB-C1A4FE0A5199Q41876243-C5D8E860-B28B-4164-9100-0B583EDD479EQ42046541-E57EE7B5-0C73-4F12-9894-D3CA73E67A7AQ45732639-7FF2C374-DA9B-4CE5-8B00-6DD2DF2143A5Q46066238-D52DB3E8-BBEA-4ECF-815A-B976D0EEA59CQ48246344-4B9B9561-0E55-44D5-8F2C-63F453E8BBF4Q52687811-2A9DDC7B-8AC9-408E-94D3-9C7FDA6C13F0Q52972104-CD58A1DA-67B8-49D3-88F7-417E67B83E8AQ55034836-FE0C90D7-0A82-4C1E-94D6-01CC1674C951
P2860
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@ast
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@en
type
label
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@ast
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@en
prefLabel
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@ast
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@en
P2093
P2860
P50
P921
P1433
P1476
Phase I clinical trial of CpG ...... d chronic lymphocytic leukemia
@en
P2093
Brian J Smith
Clive S Zent
Deborah A Bowen
James E Wooldridge
Neil E Kay
Tait D Shanafelt
Thomas E Witzig
Timothy G Call
P2860
P304
P356
10.3109/10428194.2011.608451
P577
2011-09-19T00:00:00Z